Tandem Diabetes Care (TNDM) is back on investors’ radar after recent trading moves, with the stock’s mixed short term performance prompting a fresh look at its business, profitability profile, and current valuation.

Recent trading has been volatile, with the share price jumping 11.16% on the day and 27.76% over the past week. However, the 1 year total shareholder return is still down 5.44% and the 5 year total shareholder return is down 78.38%, suggesting recent momentum is rebuilding from a weak longer term base.

If you are weighing Tandem Diabetes Care’s recent rebound against other healthcare opportunities, this could be a useful moment to scan for US-listed 40 healthcare AI stocks

With Tandem Diabetes Care trading around $19.12, carrying a value score of 5 and sitting at a discount to analyst price targets and some intrinsic estimates, is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 37.4% Undervalued

At a last close of $19.12 versus a narrative fair value of about $30.52, Tandem Diabetes Care sits at a sizeable modeled discount that hinges on a specific view of future growth and profitability.

Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels, supporting future revenue growth, margin expansion, and improved earnings.

Want to see how this pharmacy shift, projected revenue growth, and a step change in margins all line up into one valuation story? The narrative leans on a future earnings profile and a higher profit multiple that many investors usually associate with faster growing healthcare platforms. Curious which assumptions need to hold for that fair value to stack up against today’s price?

Result: Fair Value of $30.52 (UNDERVALUED)

However, there are clear watchpoints, including rising competition in insulin pumps and the execution risk that pharmacy and international shifts do not translate into the modeled margin gains.

Next Steps

With mixed signals on risks and rewards so far, this is a good time to move quickly and stress test the data yourself using our 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you only stop at one stock, you may miss opportunities that fit your style better, so put a few minutes into scanning fresh ideas with the Simply Wall St screener.

• Spot potential mispricings by hunting for quality companies trading below intrinsic estimates using our 47 high quality undervalued stocks
• Strengthen your income stream by focusing on companies with higher yields and resilience through the 10 dividend fortresses
• Prioritise resilience and sleep easier at night by filtering for companies that pass strict risk checks with the 62 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.